NCT06383702 - A Study to Evaluate Pregabalin in Painful Diabetic Peripheral Neuropathy | Biotech Hunter

Enrollment

358

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

April 1, 2025

Study Completion Date

April 15, 2025

Conditions

Painful Diabetic Neuropathy

Interventions

DRUG

pregabalin sustained-release tablets

Subjects will take pregabalin sustained-release tablets for the duration of 14 weeks. The dosage will include 165 mg daily (for the titration and the withdraw period) and 330 mg daily for the fixed-dose period.

DRUG

Placebo

Subjects will take placebo tablets for the duration of 14 weeks. The dosage will include 165 mg daily (for the titration and the withdraw period) and 330 mg daily for the fixed-dose period.